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Liposomal delivery is a well-established approach to increase the therapeutic index of drugs, 
mainly in the field of cancer chemotherapy. The implementation of remote loading techniques 
has enabled high encapsulation yields and prolonged retention of ionizable and membrane-
permeable drugs. However, polar or amphiphobic drugs with low molecular weight still 
represent a challenge and suffer from poor entrapment efficiencies. This obstacle can be 
overcome by means of lipophilic derivatization, which enables effective anchoring of the drug 
in the phospholipid bilayer. Here, we report the preparation and characterization of a new 
liposomal formulation of a derivative of lomeguatrib, a potent O6-methylguanine-DNA 
methyltransferase (MGMT) inactivator. The drug had been tested in clinical trials to revert 
chemoresistance, but was associated with a low therapeutic index. A series of lomeguatrib 
conjugates with distinct alkyl chain lengths – i.e. C12, C14, C16, and C18 – were synthesized, 
and their cytotoxicity as well as MGMT depletion activity were determined on relevant mouse 
and human glioma cell lines. Drug-containing liposomes were prepared and characterized in 
terms of loading and in vitro release kinetics. Except for the C12 derivative, the lipophilic 
lomeguatrib derivatives did not exert cytotoxic effects at 5  in the mouse glioma cell line, 
and exhibited a similar MGMT depletion activity pattern as lomeguatrib. Overall, drug 
loading could be improved by up to 50-fold with the lipophilic conjugates, and the slowest 
leakage was achieved with the C18 derivative. The present data show the applicability of 
lipophilic lomeguatrib derivatization for incorporation into liposomes, and identify the C18 
derivative as the lead compound for in vivo studies.  
  
Keywords: methylguanine-DNA methyltransferase inactivators, lomeguatrib, liposomes, 
lipophilic derivatives, drug loading, liposomal retention 
Abbreviations: BBB, blood-brain barrier; Br-Cn, bromoalkane; Br-C12, 1-bromododecane; 
Br-C14, 1-bromotetradecane; Br-C16, 1-bromohexadecane; Br-C18, 1-bromooctadecane; 
CHOL, cholesterol; DCM, dichloromethane; DLS, dynamic light scattering; DMEM, 
Dulbecco’s modified Eagle’s medium; DMF, dimethylformamide; DMSO, dimethyl 
sulfoxide; DOPC, 1,2-dioleoyl-sn-glycero-3-phosphocholine; DSC, differential scanning 
calorimetry; DSPE-PEG, N-(carbonyl-methoxypolyethylenglycol-2000)-1,2-distearoyl-sn-
glycero-3-phosphoethanolamine, Na-salt; EDTA, ethylenediaminetetraacetic acid; EPR-
effect, enhanced permeation and retention effect; FBS, fetal bovine serum; HEPES, 4-(2-
hydroxyethyl)piperazine-1-ethanesulfonic acid; horseradish peroxidase, HRP; LiH, lithium 
hydride; MGMT, O6-methylguanine-DNA methyltransferase; MLV, multilamellar vesicle; 
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O6BG, O6-benzylguanine; O6BTG, O6-(4-bromothenyl)guanine; O6BTG-C8-Glu, 8-[O6-(4-
bromothenyl)-guan-9-yl]-octyl-β-D-glucoside; O6BTG-Cn, synthesized lipophilic derivatives 
of O6BTG; PDI, polydispersity index; PBS, phosphate-buffered saline; SEC, size exclusion 
chromatography; SD, standard deviation; TEM, transmission electron microscopy; Tris, 
tris(hydroxymethyl)aminomethane; UV, ultraviolet. 
 
1. Introduction 
Liposomes have successfully been used as carriers to ameliorate the therapeutic index of 
chemotherapeutic drugs such as doxorubicin, daunorubicin and more recently vincristine and 
irinotecan (Gill et al., 1996; Ko et al., 2011; O'Brien et al., 2010; O’Brien et al., 2004). 
Passive as well as active loading methods allow the encapsulation of a broad range of drugs, 
from hydrophilic to amphiphilic and lipophilic molecules, in either the hydrophilic aqueous 
core or the surrounding phospholipid lipid bilayer. While the entrapment of polar drugs is 
often associated with low efficiency, it can be improved substantially by remote loading 
procedures as long as the compounds are ionizable and sufficiently membrane–permeable, 
which is the case with several notable examples on the market such as doxorubicin and 
vincristine sulfate liposomes (Doxil® or Marqibo®, respectively) (Boman et al., 1993; Haran 
et al., 1993; Mayer et al., 1990). Some classes of molecules, however, remain difficult to load 
into liposomes. For example, non-glycosylated purine analogues are mostly insoluble in water 
and show only marginal solubility in organic solvents. Gulati et al. termed this class of 
amphiphobic compounds as “biphasic insoluble drugs” (Gulati et al., 1998). Indeed, the 
biphasic insoluble nature of drugs like allopurinol, 8-azaguanine, and 6-mercaptopurine 
makes them challenging candidates for liposomal formulations, as neither interactions with 
the lipid bilayer nor stable retention in the inner core can be achieved (Fendler and Romero, 
1976; Liautard et al., 1991; Taneja et al., 2000). 
Lipophilic derivatization is an effective strategy for the improvement of drug loading in 
liposomes (Gabizon et al., 2006) that has enabled formulations with increased drug 
entrapment by several thousand-fold (Sasaki et al., 1987; Tokunaga et al., 1988). In this 
process, a lipophilic anchor is covalently conjugated to the drug of interest, often via 
biodegradable linkers (e.g. ester, disulfide), which dock the pharmaceutical active component 
at the liposomal bilayer.  
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Lomeguatrib (or O6BTG, short for O6-(4-bromothenyl)guanine) is a purine analogue with 
biphasic insoluble properties, and a potent inactivator and pseudo-substrate of the O6-
methylguanine-DNA methyltransferase (MGMT). Firstly synthesized in the early 90’s, 
O6BTG showed greater in vitro potency compared to O6-benzylguanine (O6BG), the very first 
MGMT inactivator tested in humans. Clinically, O6BTG has been evaluated for its ability to 
counteract MGMT-induced resistance against triazene-based chemotherapeutics such as 
temozolomide (Ranson et al., 2006) and dacarbazine (Tawbi et al., 2011). Unfortunately, 
O6BTG potentiated the hematological toxicity of alkylating antineoplastic agents at effective 
dosage, a downside shared with several other MGMT inactivators, which precluded any 
advantage over the treatment with antineoplastic agent alone (Kefford et al., 2009; Khan et 
al., 2008; Ranson et al., 2006; Sabharwal et al., 2010). In the early 2000s, the group of 
Wiessler addressed the drug’s tumor-specificity and aqueous solubility by linking glucose to 
O6BTG (Reinhard et al., 2001a; Reinhard et al., 2001b). The authors examined the ability of a 
series of conjugates to inactivate MGMT as a function of spacer length, revealing that a 
minimum of 8 carbon atoms (C8) in the spacer arm were required for adequate depletion 
activity. Nonetheless, their lead compound, 8-[O6-(4-bromothenyl)-guan-9-yl]-octyl-β-D-
glucoside (O6BTG-C8-Glu), induced higher cytotoxicity than O6BTG. While information 
regarding the water-solubility of O6BTG-C8-Glu was not provided in the study, the strong 
hydrophobic character of the linker would suggest that only a small solubility improvement 
was achieved. Given the hematological toxicity of O6BTG in humans when combined with 
alkylating agents, we hypothesized that the incorporation of O6BTG into liposomes could 
improve the drug’s therapeutic index by altering its biodistribution profile. Capitalizing on the 
benefits of long-circulating poly(ethylene glycol)-modified liposomes, the proposed approach 
could enhance drug deposition in tumors exhibiting an innate enhanced permeability and 
retention (EPR) effect. Moreover,O6BTG-loaded liposomes could also constitute a valid 
therapeutic strategy for challenging neoplasms largely lacking an EPR effect (Gao et al., 
2013), e.g. glioblastoma multiforme, provided strategies to locally permeabilize the BBB are 
put in place, such as microbubble-enhanced focused ultrasound (FUS) (Treat et al., 2007; 
Treat et al., 2012).  
In this work, the development of a liposomal formulation of O6BTG suitable for parenteral 
administration is described. A series of alkylated O6BTG derivatives (O6BTG-Cn) was 
synthesized with chain lengths ranging from C12 to C18 with the aim of increasing O6BTG 
loading in liposomes. The impact of the lipophilic anchor conjugation on the derivatives’ 
MGMT depleting activity and cytotoxic properties were assessed in temozolomide-resistant 
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glioma cells. Furthermore, liposomes loaded with the O6BTG derivatives were prepared and 
characterized. Based on the obtained experimental results, a promising lead formulation with 
highly favorable in vitro performance was identified for in vivo studies. 
 
2. Materials and Methods 
2.1 Materials 
Chloroform, cholesterol (CHOL), dimethyl sulfoxide (DMSO), ethanol, ethyl acetate, 
ethylenediaminetetraacetic acid (EDTA), 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid 
(HEPES), horseradish peroxidase (HRP), methanol, O6BG, silica gel, 
tris(hydroxymethyl)aminomethane (Tris) base, polysorbate 20, sodium phosphate dibasic 
heptahydrate, and sodium phosphate monobasic monohydrate were purchased from Sigma-
Aldrich Chemie GmbH (Buchs, Switzerland). Anhydrous dimethylformamide (DMF) was 
supplied by Acros Organics (Geel, Belgium) and dichloromethane (DCM) by Fisher 
Scientific (Reinach, Switzerland). O6BTG and O6BTG-C8-Glu were bought from Cayman 
Chemical (Ann Arbor, MI). Lithium hydride (LiH), 1-bromododecane (Br-C12; purity 98%) 
as well as 1-bromooctadecane (Br-C18; purity 97%) were purchased from abcr GmbH 
(Karlsruhe, Germany) and 1-bromotetradecane (Br-C14; purity ≥ 97%) as well as 1-
bromotetradecane (Br-C16; purity ≥ 96%) were supplied by Merck Millipore KGaA 
(Darmstadt, Germany). 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) and N-(carbonyl-
methoxypolyethylenglycol-2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine, Na-salt 
(DSPE-PEG) were bought from Lipoid GmbH (Ludwigshafen am Rhein, Germany). Tris-HCl 
was purchased from Axon Lab AG (Baden-Dättwil, Switzerland). The murine glioma cell line 
SMA-497 was derived from a spontaneous astrocytoma in a VM/Dk mouse as previously 
characterized (Ahmad et al., 2014; Fraser, 1971) and kindly provided by Dr. D. Bigner (Duke 
University, School of Medicine, Durham, NC). The human malignant glioma cell line LN-18, 
previously described by Bartussek et al. (Bartussek et al., 1999), was kindly provided by Dr. 
N. de Tribolet (Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland). Phosphate-
buffered saline (PBS), Dulbecco’s modified Eagle’s medium (DMEM, high glucose, 
pyruvate, no glutamine), DMEM (high glucose, no glutamine, no phenol red), and L-
glutamine were purchased from Life Technologies (Zug, Switzerland). Anti-human MGMT 
antibody, fetal bovine serum (FBS), NP40 cell lysis buffer, and skim milk were bought from 
Thermo Fisher Scientific AG (Reinach, Switzerland). Anti-mouse MGMT antibody was 
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purchased from R&D Systems (Minneapolis, MN). Anti-β-actin antibody, goat anti-rat IgG-
HRP antibody, and donkey anti-goat IgG-HRP antibody were purchased from Santa Cruz 
Biotechnologies (Santa Cruz, CA). Sheep anti-mouse IgG-HRP antibody was bought from GE 
Healthcare Life Sciences (Chalfont St Giles, UK). 
 
2.2 Synthesis of O6BTG derivatives 
The synthesis of lipophilic O6BTG derivatives (O6BTG-Cn) was adapted after Kjellberg et al. 
and Reinhard et al. (Fig. 1) (Kjellberg et al., 1986; Reinhard et al., 2001b). Briefly, LiH (9.7 
mg, 1.23 mmol) was suspended in 6.5 mL anhydrous DMF, added to 200 mg O6BTG (0.613 
mmol) under inert atmosphere and the temperature increased to 80 °C under constant stirring. 
Subsequently, 0.613 mmol of the respective bromoalkane (Br-Cn; Br-C12: 152.8 mg, Br-C14: 
170.0 mg, Br-C16: 187.2 mg, Br-C18: 204.4 mg) were dissolved in 4.8 mL anhydrous DMF 
and dropwise added to the reaction mixture and left under stirring for 3 h at 80 °C. After 
equilibrating to room temperature, 6.5 mL phosphate buffer (100 mM, pH 7) were added 
dropwise to stop the reaction and left stirring for further 15 min. The products were extracted 
3 times with chloroform and the combined organic phases were concentrated under reduced 
pressure at 70 °C. Purification by column chromatography on silica gel base employing 
gradient elution with ethyl acetate/DCM/ethanol (10:10:1 v/v/v) and DCM/methanol (10:1 
v/v) allowed the separation of N9 and N7 isomers yielding white solids. Analysis of O6BTG-
Cn was performed by 1H-NMR and 13C-NMR spectroscopies on a Bruker Ultra Shield at 400 
MHz (Bruker, Karlsruhe, Germany).  High resolution mass spectrometry (HRMS)-ESI was 
performed on a maXis UHR-TOF mass spectrometer (Bruker) by the MS service of ETHZ. 
Melting points of the synthesized isomers were determined by differential scanning 
calorimetry (DSC) at heating rates of 10 °C/min with a Q200 DSC System (TA Instruments, 
Eschborn, Germany) under nitrogen atmosphere using Tzero aluminium hermetic pans (TA 
Instruments). 
 
2.3 Cell culture 
SMA-497 mouse glioma cells and LN-18 human glioma cells were grown in complete 
medium (DMEM supplemented with 10% FBS and 2 mM L-glutamine) in a humidified 
atmosphere of 5% CO2 at 37 °C and routinely passaged 2-3 times per week. For cytotoxicity 
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and MGMT depleting experiments, cells were grown to about 80% confluence before use. 
Both cell lines were regularly tested for the absence of mycoplasma. More specific culture 
conditions are given in the respective sections. 
 
2.4 MGMT depleting activity of O6BTG-Cn 
The MGMT depleting activity of the O6BTG-Cn derivatives was assessed by Western blot 
adapting a protocol from Towbin et al. (Towbin et al., 1979). Cells (2 x 105 per well) were 
seeded in 6-well plates, grown for 24 h and exposed to increasing concentrations of O6BTG-
Cn (N9) for another 24 h. The medium was then replaced and after 72 h the cells were lysed 
with lysis buffer (25 mM Tris-HCl, 120 mM sodium chloride, 5 mM EDTA, 0.5% NP40 cell 
lysis buffer) (Seystahl et al., 2015). Total protein (30 μg/lane) was separated on a 12% 
acrylamide gel. After transfer to nitrocellulose membranes, the blots were blocked for 1 h in 
5% milk-Tris-buffered saline with polysorbate 20, and incubated overnight at 4 °C with the 
respective primary antibodies (anti-human MGMT, anti-murine MGMT or anti-β-actin). The 
membranes were then washed and incubated with secondary antibodies conjugated to HRP 
(sheep anti-mouse IgG-HRP, goat anti-rat IgG-HRP, and donkey anti-goat IgG-HRP) at room 
temperature for 1 h. Protein bands were detected using enhanced chemiluminescence by a 
Curix 60 table-top processor (Agfa, Mortsel, Belgium).  
 
2.5 Cytotoxicity experiments 
The cytotoxic potential of O6BTG-Cns was determined in vitro using a MTS assay 
(CellTiter® 96 Aqueous Non-Radioactive Cell Proliferation Assay, Promega, Madison, WI) 
according to manufacturer’s instructions. More specifically, SMA-497 and LN-18 cells were 
seeded at a density of 1 x 104 cells/well in 100 μL of complete medium in a 96-well plate and 
allowed to adhere for 24 h. The medium was then changed with 100 µL serum-free medium 
with 1% of DMSO containing increasing concentrations of either O6BG, O6BTG, O6BTG-C8-
Glu, O6BTG-Cn (0, 1.25, 2.5, 5, 10, 20, and 40 μM). After 24 h, the medium was replaced by 
100 μL phenol red-, serum-free DMEM and 20 μL CellTiter 96®AQueous One Solution 
Reagent. The cells were incubated for 2 h to reduce the MTS tetrazolium compound into a 
reddish formazan product, which was subsequently quantified by spectrophotometry at 
490 nm with an Infinite M200Pro plate reader (Tecan, Maennedorf, Switzerland). 
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2.6 Preparation of drug-loaded liposomes 
Small unilamellar liposomes were prepared by the lipid film hydration/extrusion method 
(Hope et al., 1985). More specifically, chloroform stock solutions of DOPC, CHOL and 
DSPE-PEG were mixed at a molar ratio of 72.5:20:7.5. O6BG and O6BTG-C8-Glu were 
dissolved in the mixed lipid solution at a drug-to-lipid ratio of 4 mol%, while O6BTG and the 
respective O6BTG-Cn were dissolved to gain drug-to-lipid ratios of 1, 2.5, 3, 4, 5 and 
7.5 mol%. In the cases of O6BG, O6BTG and O6BTG-C8-Glu, a mixture of chloroform and 
methanol (80:20 v/v final ratio) was needed for complete compound dissolution. The solvents 
were removed under reduced pressure at 60 °C, and the lipid film was stored under vacuum 
overnight. Rehydration of the lipid film was performed with PBS under vigorous vortexing at 
room temperature to give a final lipid concentration of 100 mM. The liposomes were extruded 
10 times through polycarbonate membranes of 0.05 µm pore size at room temperature using a 
Lipex 10 mL extruder (Lipex Biomembranes, Burnaby, BC, Canada), sterile filtered, and kept 
at 4 °C for a maximum of 5 days until use. Hydrodynamic diameters and PDIs were measured 
by DLS (intensity-average) using a Delsa Nano C particle analyzer (Beckman Coulter, Brea, 
CA). 
 
2.7 Cryo-transmission electron microscopy (cryo-TEM) 
Five µL of each sample was applied to a copper grid covered by holey carbon film (Quantifoil 
Multi A Micro Tools GmbH, Jena, Germany) and excess of liquid was blotted automatically 
between two strips of filter paper. Subsequently, the samples were rapidly plunged into liquid 
ethane (cooled to ~ 180 °C) in a cryobox (Carl Zeiss NTS GmbH, Oberkochen, Germany). 
Excess ethane was removed with a piece of filter paper. The samples were transferred 
immediately with a Gatan 626 cryo-transfer holder (Gatan, Pleasanton, CA) into the pre-
cooled cryo-electron microscope (Philips CM 120, Eindhoven, Netherlands) operated at 
120 kV and viewed under low dose conditions. The images were recorded with a 2k CMOS 
Camera (F216, TVIPS, Gauting, Germany). In order to minimize the noise, four images were 
recorded and averaged to one image. 
 
2.8 Determination of drug loading 
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Liposomal loading was initially measured after removing free drug by size exclusion 
chromatography (SEC) with prepacked PD-10 desalting columns (GE Healthcare Life 
Sciences, Chalfont St Giles, UK) for O6BG, O6BTG, O6BTG-C8-Glu, and all O6BTG-Cn. 
However, in further experiments SEC was omitted for all O6BTG-Cn due to their low 
partitioning into the aqueous phase, as further specified in their elution profiles presented in 
the Supplementary Information (S.1). Drug concentration in the liposome suspension was 
assessed by UV spectrophotometry using an Infinite M200Pro plate reader. Briefly, liposomes 
were diluted 1:50 in methanol and measured at a test wavelength of 286 nm against a 
reference wavelength of 350 nm to account for methanol interference. Equally diluted empty 
liposomes were used as blank. The drug concentration in the liposome suspensions was 
normalized to its phosphate content determined by a molybdane blue-based phosphate assay 
after conversion to inorganic phosphate (Morrison, 1964). 
 
2.9 In vitro release kinetics 
Drug release from liposomes was determined in vitro following a protocol developed by 
Shabbits et al. (2002). This assay is based on the transfer of lipophilic drugs from donor drug-
containing liposomes to acceptor multilamellar vesicles (MLVs) mimicking the in vivo drug 
transfer rate to hydrophobic pools. Briefly, donor O6BTG-Cn-loaded liposomes were 
incubated with acceptor MLVs at a 1:100 mol ratio in 4-(2-hydroxyethyl)piperazine-1-
ethanesulfonic acid (HEPES)-buffered saline for 24 h at 37 °C under constant stirring. 
Samples were withdrawn at various times (0, 0.5, 1, 2, 4, 8, and 24 h) and centrifuged at 
1600 x g for 10 min to separate acceptor MLVs from donor liposomes, which remained in the 
supernatant. The drug amount in the supernatant was assessed by high-performance liquid 
chromatography (HPLC). Details on MLV preparation and drug quantification by HPLC are 
available as Supplementary Information (S.2). 
 
2.10 Statistical analysis 
Statistics were performed with SigmaPlot 13.0 software (Systat Software Inc., San Jose, CA). 
All data presented are means ± SD of at least three independent samples. One-way ANOVA 
combined with a Tukey test for pairwise comparison was performed to distinguish differences 
between test groups defining a p value of ≤ 0.05 as statistically significant. 
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3. Results and discussion 
3.1 Synthesis of O6BTG derivatives 
The alkylation of O6BTG (Fig. 1) was a one-step synthesis with a yield of ca. 80% for the 
isomeric mixture (Table 1). O6BTG-Cn were prepared from the respective Br-Cn and O6BTG 
via nucleophilic substitution, yielding two different isomers at the respective N7 or N9 
position of the guanine moiety. The structures of all O6BTG-Cn (N7 and N9) were determined 
by 1H-NMR and 13C-NMR spectroscopies (Supplementary Information: S.3). Melting points 
obtained by DSC were in the range of 112 to 122 °C for the N7 derivatives, and in the range 
of 99 to 105 °C for the N9 derivatives (Table 1). An increase in chain length led to a decrease 
in melting points in the N7 isomers, whereas the opposite trend was recorded for the N9 
isomers. Both the melting entropy and enthalpy generally increased with increasing chain 
lengths. For the alkyl chains of the N9 isomer it might, however, be easier to establish van der 
Waals interactions due to a larger distance to the bromothenyl-residue compared to the N7 
isomer. Ordered domains may attenuate the increase in melting entropy as a function of chain 
length, making the increase in melting enthalpy the dominating factor for the N9 and leading 
to a rise in melting points (Zhang et al., 2014; Zhang and Maginn, 2014). With regard to the 
N7, the enthalpy increase compared to the one of the N9 might be reduced, resulting in a 
melting point decrease. As previously observed by Kjellberg et al., the chosen synthetic 
strategy favored the N9 isomer (Kjellberg et al., 1986).  
Fig. 1. Synthesis scheme of O6BTG-Cn. 
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Table 1. List of synthesized O6BTG-Cn.    
Compound Abbreviation Yield (%) Tm (°C) 
O6-(4-bromothenyl)-7-dodecylguanine (1a) O6BTG-C12 (N7) 23 122 
O6-(4-bromothenyl)-9-dodecylguanine (1b) O6BTG-C12 (N9) 54 99 
O6-(4-bromothenyl)-7-tetradecylguanine (2a) O6BTG-C14 (N7) 27 118 
O6-(4-bromothenyl)-9-tetradecylguanine (2b) O6BTG-C14 (N9) 57 101 
O6-(4-bromothenyl)-7-hexadecylguanine (3a) O6BTG-C16 (N7) 27 118 
O6-(4-bromothenyl)-9-hexadecylguanine (3b) O6BTG-C16 (N9) 56 103 
O6-(4-bromothenyl)-7-octadecylguanine (4a) O6BTG-C18 (N7) 24 112 
O6-(4-bromothenyl)-9-octadecylguanine (4b) O6BTG-C18 (N9) 57 105 
 
 
3.3 MGMT depleting activity of O6BTG-Cn 
Several former studies evaluating alternative O6BTG derivatives have reported that N7-
substitution of MGMT inactivators consistently resulted in complete loss of MGMT depleting 
activity (Chae et al., 1994; Moschel et al., 1992). Based on these findings, we investigated the 
depleting activity of one N7 isomer, O6BTG-C12 (N7), and compared it to its N9 counterpart. 
A direct comparison of the two isomers in SMA-497 glioma cells (Fig. 2) revealed that the 
N9 was more active than the N7. Indeed, the N7 isomer did not show any significant 
depletion on SMA-497 cells in the tested concentration range. These results confirmed 
previous work (Chae et al., 1994; Moschel et al., 1992), and might be explained by the 
structural similarity between the N9 isomer and the natural target of MGMT, the DNA, in 
which the nitrogen atom at position 9 of the guanine base is linked to the 1’ carbon atom of 
the deoxyribose.  
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Fig. 2. MGMT inactivation by O6BTG-C12 (N7 and N9) in SMA-497 glioma cells by representative Western 
blot images. The untreated 100% control is abbreviated by CTL. 
 
To understand the isomer-dependent depleting activity, we investigated the isomers’ binding 
mechanisms to MGMT using molecular dynamics (MD) simulations. Chemical reactions 
between the protein and the ligand were not investigated, since this requires a more complex 
simulation protocol which would go beyond the purpose of this work. The binding site of 
human MGMT with O6BG was used for binding studies with O6BTG and O6BTG-C12 (N7 
and N9) (Wibley et al., 1995; Wibley et al., 2000). Indeed, the binding mechanism of the 
active part of the N9 isomer was analogous to the one of O6BTG (Figs. 3A, B); in addition, 
the arrangement of the alkyl chain was consistent with the findings reported for O6BTG-C8-
Glu (N9) by Reinhard et al. (Reinhard et al., 2001c). Interestingly, the N7 isomer also 
exhibited a similar pose within the binding pocket (Fig. 3C), but the binding stability was 
dependent on the orientation of the aliphatic chain. Unbinding events that destabilized the 
protein-ligand interaction were found when the alkyl chain was oriented similarly to the one 
of the N9 isomer as illustrated in Fig. 3D. However, stable binding is most likely a 
prerequisite for the covalent reaction between protein and MGMT inhibitors, explaining the 
poor MGMT depleting activity of the N7 isomer. An additional set of simulations was 
performed for O6BTG-C18 (N7 and N9); molecular trajectories showed a behavior analogous 
to O6BTG-C12 isomers. A detailed discussion of the performed MD simulations is provided 
in the Supporting Information (S.4). 
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Fig. 3. Representative MGMT binding poses of O6BTG (A), O6BTG-C12 (N9) (B) and O6BTG-C12 (N7) (C). 
Unbinding event of O6BTG-C12 (N7) (D).  
Given the confirmed superior MGMT depleting effect, the N9 derivatives were selected for 
all further experiments.  
 
The impact of the alkyl chain length on the drug activity of the N9 isomers was then evaluated 
by monitoring the levels of intracellular MGMT protein levels on SMA-497 and LN-18 cells 
at increasing O6BTG-Cn concentrations. As illustrated in Fig. 4, all derivatives inactivated 
MGMT in a concentration-dependent manner and depleted MGMT with a similar potency as 
O6BTG on both tested cell lines. Interestingly, O6BTG as well as O6BTG-Cn appeared to 
have a stronger MGMT depletion effect on the human-derived cell line LN-18 than on the 
mouse-derived one SMA-497. Possibly, interspecies variability of the MGMT protein led to 
different affinities for the same purine analog (Crone et al., 1994).  
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Fig. 4. MGMT depletion by O6BTG and O6BTG-Cn (N9) in SMA-497 (A) and LN-18 glioma cells (B) at 
different concentrations, indicated by representative Western blot images. The untreated 100% control is 
abbreviated CTL. 
 
3.2 In vitro cytotoxicity of O6BTG-Cn (N9) 
The cytotoxicity of the O6BTG-Cn (N9) derivatives was assessed in murine SMA-497 and 
human LN-18 cells, and compared to those of the parent drug and two established MGMT 
inactivators, namely O6BG and O6BTG-C8-Glu. Similar to the parent drug, a concentration-
dependent decrease of cell viability was found for all derivatives in both cell lines, with a 
more prominent effect in LN-18 cells (Figs. 5 A-D). Although MGMT inactivators are not 
expected to be highly cytotoxic given that their target protein does not hold  to current 
knowledge  housekeeping tasks in the cell (Margison et al., 2003; Tsuzuki et al., 1996), off-
target cytotoxicity can occur. Remarkably, aside from O6BTG-C12, all derivatives showed 
low cytotoxicity in the SMA-497 cell line. On the other hand, in LN-18 cells O6BTG-C12, 
O6BTG-C14 and O6BTG-C16 induced a strong decrease in cell viability after a 24 h 
incubation period at a 40 μM concentration, reaching 25% survival for O6BTG-C12 (Fig. 5 
D). O6BTG-C18, the derivative with the longest alkyl chain, did not show prominent toxicity 
in the tested concentration range, and was in fact significantly less toxic than O6BTG at 10-
40 μM in SMA-497 cells and 5-20 μM in LN-18 cells (Figs. 5 B, D). It is noteworthy that 
toxic effects appeared to be inversely related to the alkyl chain length in both cell lines. Given 
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their strong lipophilic nature, the O6BTG-Cn derivatives might bear a greater potential to 
permeate biological membranes than the parent drug O6BTG, making them more likely to 
reach the intracellular space. With regard to the alkyl chain length, derivatives with longer 
chains might associate with plasma membranes more strongly, minimizing further transfer to 
subcellular compartments and, in turn decreasing cytotoxic effects as demonstrated for 
O6BTG-C18 (Locatelli et al., 2008). Nevertheless, as emphasized in section 3.3, enough 
O6BTG-C18 molecules may still gain access to the cell and efficiently deplete MGMT. Based 
on its low cytotoxic potential compared to the parent compound and the other O6BTG-Cn, 
O6BTG-C18 may thus represent a suitable alternative for a potentially non-toxic AGT 
inactivation in vivo. 
 
A 
 
 
B 
 
C 
 
D 
 
  
Fig. 5. Cell viability data of SMA-497 (A, B) and LN-18 cells (C, D) after incubation with established MGMT 
inactivators and with O6BTG-Cn, respectively. Data for O6BTG are illustrated in both panels, respectively. Data 
are means ± SD (n = 3), *p ≤ 0.05, **p ≤ 0.01 O6BTG-C18 vs. O6BTG. 
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3.6 Characterization and drug loading of liposomal O6BTG-Cn formulations 
The different O6BTG-Cn were passively loaded into DOPC-based liposomes using the lipid 
film hydration method followed by extrusion. Empty and drug-loaded liposomes had a mean 
hydrodynamic diameter of ca. 75 nm with a PDI below 0.2 (Supplementary Information: S.5). 
Considering that tumoral deposition depends on nanoparticle size, the obtained hydrodynamic 
diameter might be suitable for passive delivery via the EPR effect alone or preferably in 
combination with localized BBB permeabilization, for instance with microbubble-enhanced 
FUS (Sunoqrot et al., 2014; Treat et al., 2007). Cryo-TEM-based images of empty and 
O6BTG-C18-loaded liposomes (4 mol%) showed mainly spherical unilamellar particles with 
very few bi-lamellar and invaginated liposomes (Fig. 6). No drug precipitates were apparent 
in the recorded images.  
 
Fig. 6. Cryo-TEM images of (A) empty and (B) O6BTG-C18-loaded liposomes at a drug loading of 4 mol%. 
 
Drug loadings of O6BG, O6BTG, O6BTG-C8-Glu, and O6BTG-Cn were measured and 
compared at an initially added drug concentration of 4 mol% (Fig. 7). O6BG and O6BTG 
revealed loadings of <0.02 mol% and 0.08 ± 0.03 mol%, respectively, with entrapment 
efficiencies below or equal to 2%. The use of O6BTG conjugated to an octyl-glucose linker 
led to a 10-fold increase in drug loading (0.87 ± 0.13 mol%), likely a result of a stronger 
hydrophobic interaction of the C8-moiety with the liposomal bilayer. O6BTG conjugations 
with simple alkyl chains gave rise to significantly increased loadings, reaching entrapment 
efficiencies of more than 85%. 
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Fig. 7. Drug loading of different MGMT inactivators after SEC. Data are means ± SD (n = 3), ***p ≤ 0.001. 
Having established the superior drug loading of the lipophilic derivatives over O6BTG, the 
maximum loading capacity was determined. Due to the extremely low aqueous solubility of 
the alkylated compounds, the liposomes were only purified by eliminating the precipitated, 
unentrapped O6BTG-Cn via filtration during the extrusion procedure. Maximum drug loading 
was reached at the initially added drug concentrations of 4 and 5 mol% (Fig. 8). Above these 
concentrations, the formulations were not stable, as evidenced by the formation of precipitates 
within 24 h (data not shown), which reflected the oversaturation of the system. At an initial 
N9) by Reinhard et al.  ADDIN EN.CITE  ADDIN EN.CITE.DATA ( HYPERLINK \l "_
ENREF_29" \o "Reinhard, 2001 #1114" Reinhard et al., 2001c). Interestingly, the N7 iso
mer also exhibited a similar pose within the binding pocket (Fig.cal lipid chain length of 
O6BTG-C18 and the main liposomal lipid. With up to 50-fold higher loading compared to the 
parent drug, similar drug loading behaviors were observed with all O6BTG-Cn.  
 
Fig. 8. Drug loading curves of O6BTG, O6BTG-C12, O6BTG-C14, O6BTG-C16, and O6BTG-C18. Data are 
means ± SD (n = 3). 
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3.7 Liposomal drug retention in vitro 
The release kinetics of the liposomal formulation was monitored in vitro over 24 h at 37 °C 
with an assay using MLVs as acceptor compartment (Shabbits et al., 2002). The release rates 
correlated with the alkyl chain length (Fig. 9). The O6BTG-C12 and O6BTG-C14 derivatives 
were transferred very quickly to the surrounding MLVs and already after 1 h, more than 60% 
of the loaded drug had distributed to the MLV population. O6BTG-C16 was transferred to an 
extent lower than 30% within the same time frame, while with O6BTG-C18 the drug retention 
was much higher and less than 40 and 60% of the C18 derivative was released after 8 h and 
24 h, respectively. 
 
Fig. 9. Drug retention profiles of different O6BTG-Cn in liposomes. Data are means ± SD (n = 3-4). 
The improved liposomal retention observed for O6BTG-Cn with longer alkyl chains can be 
attributed to an increase of hydrophobic interactions with the lipid bilayer, which would 
stabilize the drugs’ anchoring (Shabbits et al., 2002). It is important to mention that the alkyl 
chain length of O6BTG-C18 is identical to the main lipid of our liposomal formulation, 
DOPC, which might minimize membrane perturbation while enhancing membrane 
embedding for this derivative. 
With regard to a future in vivo application, the incorporation of O6BTG-C18 into long-
circulating PEGylated liposomes may be suitable for the enhancement of the drug’s  
biological half-life, a prerequisite for improved tumor deposition, while ensuring sustained 
release at the tumoral site.       
 
Conclusion 
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This study presents several novel long-circulating liposomal formulations of MGMT 
inactivator derivatives that may increase the tumor deposition via the EPR-effect and/or after 
localized BBB permeabilization. Given the marginal liposomal loading of highly potent but 
low tumor-specific MGMT inactivators such as O6BG and O6BTG, lipophilic drug 
derivatization was utilized to increase liposomal incorporation. The MGMT depleting activity 
of O6BTG was preserved in the lipophilic conjugates, and especially in the derivative with the 
longest alkyl chain length (C18), which did not exhibit conspicuous cytotoxicity, and was in 
fact less toxic than O6BTG. The sustained drug retention of O6BTG-C18 in PEGylated 
liposomes in combination with the long-circulating behavior of the carrier can alter the drug’s 
biodistribution and improve its in vivo performance, making this liposomal formulation an 
eligible candidate for future MGMT-induced chemoresistant tumor therapies. The strategy 
described could potentially be used for other guanine-based MGMT inactivators in the future. 
Studies evaluating the in vivo efficacy of O6BTG-C18-based liposomes in a glioma-bearing 
rodent animal model together with temozolomide are currently ongoing.  
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